<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02876328</url>
  </required_header>
  <id_info>
    <org_study_id>C15-33</org_study_id>
    <secondary_id>PREVACEBL3005</secondary_id>
    <nct_id>NCT02876328</nct_id>
  </id_info>
  <brief_title>Partnership for Research on Ebola VACcinations</brief_title>
  <acronym>PREVAC</acronym>
  <official_title>Partnership for Research on Ebola VACcinations (PREVAC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia Project (PREVAIL)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of three vaccine
      strategies that may prevent Ebola virus disease (EVD) events in children and adults.
      Participants will receive either the Ad26.ZEBOV (rHAd26) vaccine with a MVA-BN-Filo (MVA)
      boost, or the rVSVΔG-ZEBOV-GP (rVSV) vaccine with or without boosting, or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and immunogenicity of two Ebola virus
      disease (EVD) vaccines, Ad26.ZEBOV (rHAd26) and rVSVΔG-ZEBOV-GP (rVSV), in children and
      adults. These vaccines will be studied using three different strategies: the rHAd26 vaccine
      plus a MVA-BN-Filo (MVA) boost, and the rVSV vaccine with or without boosting.

      Participants will be randomized into five groups: the Ad26.ZEBOV vaccine with an MVA boost,
      the rVSV vaccine with or without boosting, or one of two placebo groups. At Day 0 (study
      entry), participants will receive the Ad26.ZEBOV vaccine, the rVSV vaccine, or placebo.

      At Day 56, participants assigned to the rVSV vaccine without a boost and the two placebo
      groups will receive placebo. Those initially given the Ad26.ZEBOV vaccine will receive the
      MVA boost. Those assigned to the boosted rVSV group will receive the rVSV boost.

      Additional study visits will occur on Days 7, 14, 28, and 63, and at Months 3, 6, and 12.
      Study follow-up may continue for up to 5 years. Study visits may include blood collection and
      other assessments.

      Some participants may take part in substudies, which will include blood or saliva collection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 31, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Ebola virus glycoprotein (GP-EBOV) antibody response</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>Antibodies to the Ebola virus glycoprotein will be measured with the Filovirus Animal Nonclinical Group (FANG) ELISA assay if available. Other assays may also be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of serious adverse events (SAEs)</measure>
    <time_frame>Measured through Month 12</time_frame>
    <description>SAEs as defined in the protocol</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">4500</enrollment>
  <condition>Ebola Virus Disease</condition>
  <arm_group>
    <arm_group_label>Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the Ad26.ZEBOV (rHAd26) vaccine at Day 0 followed by an MVA-BN-Filo (MVA) boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (0.5 mL)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by a placebo boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive the rVSVΔG-ZEBOV-GP (rVSV) vaccine at Day 0 followed by an rVSV boost at Day 56.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (1 mL)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo at Day 0 followed by a placebo boost at Day 56.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.ZEBOV</intervention_name>
    <description>0.5 mL at a dose of 5x10^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost</arm_group_label>
    <other_name>rHAd26</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-Filo</intervention_name>
    <description>0.5 mL at a dose of 1x10^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>Ad26.ZEBOV (rHAd26) vaccine + MVA-BN-Filo (MVA) boost</arm_group_label>
    <other_name>MVA</other_name>
    <other_name>MVA-mBN226B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rVSVΔG-ZEBOV-GP</intervention_name>
    <description>1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost</arm_group_label>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost</arm_group_label>
    <other_name>rVSV</other_name>
    <other_name>V920</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>Placebo (0.5 mL)</arm_group_label>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + placebo boost</arm_group_label>
    <arm_group_label>Placebo (1 mL)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rVSV boost</intervention_name>
    <description>1 mL at a nominal dose of 2x10^7 pfu/mL administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children</description>
    <arm_group_label>rVSVΔG-ZEBOV-GP (rVSV) vaccine + rVSV boost</arm_group_label>
    <other_name>rVSVΔG-ZEBOV-GP</other_name>
    <other_name>rVSV</other_name>
    <other_name>V920</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent/assent

          -  Age greater than or equal to 1 year

          -  Planned residency in the area of the study site for the next 12 months

          -  Willingness to comply with the protocol requirements

        Exclusion Criteria:

          -  Fever greater than 38º Celsius

          -  History of EVD (self-report)

          -  Pregnancy (a negative urine pregnancy test is required for females of child-bearing
             potential, i.e., females who have experienced menarche or who are aged 14 years and
             older)

          -  Positive HIV test for participants less than 18 years of age

          -  Reported current breast-feeding

          -  Prior vaccination against Ebola (self-report)

          -  Any vaccination in the past 28 days or planned within the 28 days after randomization
             (initial vaccination)

          -  In the judgement of the clinician, any clinically significant acute/chronic condition
             that would limit the ability of the participant to meet the requirements of the study
             protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yazdan Yazdanpannah</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdoul Habib Beavogui</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Formation et de Recherche en Santé Rurale de Mafèrinyah</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Kieh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Redemption Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bailah Leigh</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sierra Leone</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre national de formation et de recherche en santé rurale (Maferyniah)</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Abdoul Habib Beavogui</last_name>
      <phone>+224 628045352</phone>
      <email>beavoguia_h@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Landreah</name>
      <address>
        <city>Conakry</city>
        <country>Guinea</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Katoudi</last_name>
      <phone>+224625258456</phone>
      <email>ldh.coordo.prevac@guinee.alima.ngo</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Redemption Hospital</name>
      <address>
        <city>Monrovia</city>
        <country>Liberia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Brown</last_name>
      <phone>+231886585479</phone>
      <email>brownsarah2006@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre pour le Développement des Vaccins (CVD)</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sambo O. Sow</last_name>
      <phone>223 7634 8947</phone>
      <email>ssow@som.umaryland.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Clinical Research Center (UCRC)</name>
      <address>
        <city>Bamako</city>
        <country>Mali</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seydou Doumbia</last_name>
      <phone>223 76 46 13 39</phone>
      <email>sdoumbi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mambolo Clinic</name>
      <address>
        <city>Kapesseh</city>
        <country>Sierra Leone</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bailah Leigh</last_name>
      <phone>23276693102</phone>
      <email>bailahleigh@yahoo.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Guinea</country>
    <country>Liberia</country>
    <country>Mali</country>
    <country>Sierra Leone</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2016</study_first_posted>
  <last_update_submitted>May 16, 2018</last_update_submitted>
  <last_update_submitted_qc>May 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ebola Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

